“Public health systems should pay for GLP-1 drugs to treat obesity.”
GLP-1 receptor agonists such as semaglutide (Wegovy) and tirzepatide (Zepbound/Mounjaro) produce weight loss of 15–20% in trials and cut cardiovascular events. They are also expensive, typically needed for life, and potentially eligible for a large share of the population.
The UK's NHS has begun a phased rollout of tirzepatide, and the US Medicare programme began covering GLP-1s for some obesity patients in 2026 after price deals with manufacturers. The core disputes are cost-effectiveness at scale, how long benefits last, who should be prioritised, and whether drugs should take money from prevention.
Tax- or insurance-funded systems (NHS, Medicare/Medicaid, European social insurance) that decide which treatments to cover.
GLP-1 and dual GIP/GLP-1 receptor agonists approved for weight management: semaglutide, tirzepatide and successors, including oral forms.
Cover without prohibitive co-payments for at least the patients most likely to benefit. Covering every adult with obesity is a much stronger claim.
These are the first drugs to produce large, sustained weight loss, and semaglutide has been shown to cut heart attacks, strokes and cardiovascular deaths in people with obesity and heart disease.
In STEP-1, semaglutide produced about 15% weight loss over 68 weeks versus about 2% with placebo. In SELECT, 17,604 people with obesity and cardiovascular disease (without diabetes) had 20% fewer major cardiovascular events on semaglutide. Tirzepatide produced about 21% weight loss at the highest dose in SURMOUNT-1.
Wilding et al. (2021). NEJM, 384, 989–1002; Lincoff et al. (2023). NEJM, 389, 2221–2232; Jastreboff et al. (2022). NEJM, 387, 205–216.
Limitation
Trials were funded by manufacturers. Outcome benefits are proven for people with existing cardiovascular disease; for lower-risk people they are projected.
Obesity is a chronic disease with strong genetic and environmental drivers, not a moral failing. Refusing effective treatment we would provide for other chronic diseases is discriminatory, and leaves access to those who can pay privately.
Twin and adoption studies estimate the heritability of body mass index at around 40–70%. The WHO and many medical bodies classify obesity as a chronic disease.
Elks et al. (2012). Variability in the Heritability of Body Mass Index: A Systematic Review and Meta-Regression. Frontiers in Endocrinology, 3, 29.
Limitation
Heritability within a population does not explain why obesity rose so fast across whole populations; environment is key.
Prices are falling fast as competition grows and governments negotiate. At lower prices, the drugs become cost-effective for many patients, and cost offsets from avoided heart disease, diabetes and joint replacements grow.
Under a November 2025 agreement, Medicare pays $245 a month for semaglutide and tirzepatide, with patients paying $50; CMS's BALANCE model opens coverage to about 10% of Medicare enrollees with obesity plus specific conditions from mid-2026. NICE recommended tirzepatide for NHS use with a phased rollout from 2025.
CMS (Dec. 2025). BALANCE model announcement; NICE (2024). Technology appraisal TA1026: Tirzepatide for managing overweight and obesity.
Limitation
Even at $245 a month, covering a large share of the population would cost tens of billions a year.
Most weight comes back when people stop, so patients may need the drugs for life. That makes the total cost enormous and the value dependent on adherence, which is low in real-world use.
In the STEP-1 extension, participants regained about two-thirds of the weight they had lost within a year of stopping semaglutide. Real-world data suggest a large share of patients stop within a year.
Wilding et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes, Obesity and Metabolism, 24(8), 1553–1564.
Limitation
Lifelong treatment is accepted for other chronic conditions such as hypertension and diabetes.
Health budgets are finite. Covering GLP-1s for everyone eligible would displace other treatments, and might divert attention and money from changing the food environment, which affects everyone.
The US Congressional Budget Office estimated in 2024 that allowing Medicare to cover anti-obesity drugs would increase federal spending by about $35 billion over 2026–2034, with savings from better health offsetting only a small fraction.
Congressional Budget Office (Oct. 2024). How Would Authorizing Medicare to Cover Anti-Obesity Medications Affect the Federal Budget?
Limitation
The CBO estimate predates the price deals. Prevention and treatment are not mutually exclusive.
Long-term safety at population scale is unknown. Side effects include gastrointestinal problems, loss of muscle along with fat, and rare serious events, and millions of healthier people taking drugs for decades is untested.
Trials report frequent nausea and gastrointestinal effects leading to discontinuation in a few percent of patients; pancreatitis, gallbladder disease and loss of lean mass (a substantial share of weight lost) are monitored concerns.
Product labelling for Wegovy and Zepbound (FDA); Neeland, Linge & Birkenfeld (2024). Changes in lean body mass with GLP-1-based therapies. Diabetes, Obesity and Metabolism, 26(Suppl. 4).
Limitation
GLP-1 drugs have been used for type 2 diabetes since 2005, giving long safety experience at lower doses.
GLP-1 drugs produce substantially more weight loss than previous obesity treatments.
Most patients regain weight after stopping.
The drugs' price is the main determinant of their cost-effectiveness for public payers.